Diamond Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome affecting about 5 to 7 per million live births1 2. It primarily causes severe anemia due to the bone marrow's inability to produce enough red blood cells3 1. With appropriate treatment, most patients with DBA can have a normal life expectancy, although lifelong management is necessary4 5. This article provides a comprehensive overview of the signs and symptoms, causes, diagnosis, treatment options, prevention, associated conditions, and daily management of DBA.
Signs and Symptoms
Diamond Blackfan anemia typically presents within the first year of life, often before 12 months of age2 6. The hallmark symptom is severe anemia characterized by macrocytic red blood cells (larger than normal) and a low reticulocyte count (young red blood cells), reflecting erythroid failure in the bone marrow3 786.
About half of DBA patients also exhibit congenital malformations, frequently involving the head and face (cephalic area) and the extremities, especially thumb abnormalities8 910. Growth delay or short stature is common among affected individuals, which may be worsened by chronic anemia and treatment side effects11 121314.
Common symptoms and signs include:
- Pale skin and mucous membranes due to anemia15 3
- Fatigue and low energy levels, sometimes noticeable even during infant feeding15 2
- Rapid heartbeat (tachycardia) as the body compensates for low oxygen delivery15 3
- Shortness of breath or difficulty breathing15
- Physical anomalies such as small or low-set ears, small head, webbed neck, and heart defects15 9
- Delayed growth and puberty compared to peers11 13
Some patients with milder forms may not show symptoms until adolescence or adulthood15 .
Diamond Blackfan anemia is a lifelong condition starting at birth that impairs red blood cell production, leading to severe anemia and sometimes physical abnormalities. Early diagnosis and treatment are crucial to managing symptoms and improving quality of life. 1516
Causes and Risk Factors
DBA is primarily caused by heterozygous loss-of-function mutations or deletions in more than 20 ribosomal protein (RP) genes, which are essential for ribosome biogenesis and protein synthesis4 171819. The most frequently mutated gene is RPS19, accounting for about 25% of cases4 17.
These genetic mutations lead to defective ribosome production, impairing erythropoiesis (red blood cell formation) and causing erythroid hypoplasia (reduced red blood cell precursors in bone marrow) 181978. The resulting failure to produce sufficient red blood cells causes the macrocytic anemia characteristic of DBA7 8.
The exact mechanisms behind the tissue-specific defects seen in DBA and other ribosomopathies remain poorly understood20 21. Additionally, some cases involve mutations in non-ribosomal genes such as GATA1, which plays a role in early red blood cell development11 22.
DBA is inherited in an autosomal dominant pattern with variable penetrance, but many cases arise from new (de novo) mutations without family history4 2215.
DBA is a ribosomopathy caused by haploinsufficiency of ribosomal proteins, leading to defective ribosome biogenesis and selective failure of red blood cell production. 18204
Related Stories
Diagnostic Process
Diagnosing DBA usually occurs during infancy but can be challenging due to overlapping features with other bone marrow failure syndromes23 224. A thorough diagnostic workup includes clinical evaluation, family history, laboratory tests, and genetic analysis23 2.
Key diagnostic criteria include:
- Onset of anemia before 12 months of age6 25
- Macrocytic anemia with low reticulocyte count, but normal white blood cell and platelet counts7 8625
- Bone marrow biopsy showing erythroid hypoplasia with normal overall cellularity but reduced erythroid precursors7 86
- Elevated erythrocyte adenosine deaminase (eADA) activity, a useful biomarker elevated in 80–85% of DBA patients26 2728
- Identification of pathogenic variants in ribosomal protein genes through molecular genetic testing confirms diagnosis23 1728
Differential diagnosis includes other inherited bone marrow failure syndromes and acquired anemias, which must be ruled out23 24. Prenatal diagnosis is possible in families with known mutations15 .
Diagnostic Criteria for Classical Diamond-Blackfan Anemia:
- Age of onset less than 12 months
- Macrocytic anemia without other significant cytopenias
- Reticulocytopenia
- Bone marrow with normal cellularity but lack of erythroid precursors6
Treatment Options
Treatment for DBA focuses on managing anemia, preventing complications, and improving quality of life. Due to clinical heterogeneity, therapy must be individualized29 513.
Corticosteroids
Corticosteroids are the first-line pharmacologic treatment for patients over 1 year of age who require transfusions4 5. Steroids stimulate the bone marrow to increase red blood cell production, often raising hemoglobin levels within 2 to 4 weeks30 28.
However, only 20–30% of patients maintain a long-term response to steroids4 5. Steroid therapy is generally avoided in infants under 1 year due to potential side effects4 5. Long-term steroid use can cause significant adverse effects such as osteoporosis, diabetes, and immunosuppression12 14.
Blood Transfusions
Patients who do not respond to steroids or are too young to receive them require regular red blood cell transfusions to maintain adequate hemoglobin levels4 530. Transfusion dependency is common in infants prior to steroid therapy initiation4 5.
While transfusions provide rapid symptom relief, chronic transfusion therapy leads to iron overload, necessitating additional treatment31 32.
Iron Chelation Therapy
Iron overload from repeated transfusions can damage organs such as the liver, heart, and endocrine glands. Iron chelation therapy uses medications to remove excess iron and prevent toxicity31 32. Effective and intensive chelation is essential for long-term management in transfusion-dependent patients31 3228.
Hematopoietic Stem Cell Transplant
Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for DBA4 533. It involves replacing the patient's defective bone marrow with healthy donor stem cells.
HSCT success depends on donor matching, patient age, and disease severity4 33. Matched sibling donors offer the best outcomes, but donor availability and high treatment costs limit its use4 33. HSCT carries risks of severe complications and is considered on a case-by-case basis30 .
Other Treatments
Research into novel therapies such as gene therapy and interferon treatment is ongoing but not yet standard care31 34. Supportive care may include vitamin D supplementation and monitoring for complications28 .
“Treatment options for Diamond-Blackfan anemia include: Corticosteroids as first-line treatment for patients older than 1 year with 20–30% long-term response but limited by side effects; Blood transfusions for steroid non-responders and infants with risk of iron overload; Iron chelation therapy essential to prevent iron toxicity from transfusions; Hematopoietic stem cell transplant is the only curative option but requires donor match and has high risk and cost. ”305
Prevention Strategies
As a congenital genetic disorder, DBA cannot be prevented2 5. However, genetic counseling is recommended for affected families to understand inheritance patterns and risks for future children5 13. Prenatal testing may be offered when a familial mutation is known15 .
Corticosteroids can improve red blood cell production in many DBA patients, but long-term use requires careful monitoring due to side effects. Transfusions and iron chelation are vital for those who do not respond to steroids. 12314
Associated Conditions
Patients with DBA have an increased risk of developing certain serious conditions, including:
- Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) 412
- Solid tumors4 12
- Endocrine dysfunctions such as osteoporosis and diabetes, often related to chronic steroid use and iron overload12 14
Regular monitoring for these complications is an important part of long-term care12 1435.
Daily Life and Management
Living with DBA requires lifelong medical care and lifestyle adjustments. Regular follow-up visits are essential to monitor anemia, treatment side effects, and complications5 13. Multidisciplinary care involving hematologists, endocrinologists, and other specialists improves outcomes5 13.
Growth delays and delayed puberty are common and may require additional support11 13. Emotional support for patients and families is critical, as the diagnosis and chronic nature of DBA can cause significant distress5 13.
“The management of Diamond Blackfan anemia demands ongoing care and a tailored approach to improve quality of life and monitor for complications.”
— Dana-Farber-Boston Children’s Hospital30
Common Questions
A diagnosis of DBA can be overwhelming for families, but with proper treatment, most patients can live long and healthy lives4 5. Emotional support and education are vital components of care5 13.
Patients and families should maintain close communication with healthcare providers and promptly report worsening symptoms such as increased fatigue or infections15 . Emergency care is necessary for severe anemia symptoms or sudden neurological signs15 .
